BIOVIT: Bio Vitos Pharma AB (publ) - Summary | Jitta

Bio Vitos Pharma AB (publ)

SWE:BIOVIT

Notice
Stock data is unavailable or the company’s delisted.
Price
kr0.12
Loss Chance
58.0%
1.32JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (17)
Recent Business Performance (19)
Financial Strength (43)
Return to Shareholders (5)
Competitive Advantage (19)
Jitta Signs
Revenue and EarningEarning loss detected in 2024
Operating MarginDeclined
Recent Business PerformanceEarning decline 144.92% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
1.32
100.00%
2.88
97.44%
2.88
97.44%
4.03
10.43%
1.89
100.00%
3.62
36.38%
COMPANY DESCRIPTION
Bio Vitos Pharma AB (publ) operates as a medical technology company in Sweden and internationally. The company develops and commercializes Helge, which detects hemolysis in vacuum tubes and blood gas samples. It serves emergency departments in the European Union and the United States. It has a collaboration agreement with KFUM Kalmar to conduct a research study. The company was formerly known as Hemcheck Sweden AB (publ) and changed its name to Bio Vitos Pharma AB (publ) in December 2023. Bio Vitos Pharma AB (publ) was incorporated in 2010 and is based in Solna, Sweden.